ASKA Pharmaceutical HoldingsASKA Pharmaceutical Holdings CO., Ltd.4886東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥8 is left as operating profit. Revenue changed +10.9% from the prior year, operating profit +9.4%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 7.6% | 0.68× | 5.2% | 1.83× | 9.4% |
| 2023 | 7.0% | 0.71× | 5.0% | 1.80× | 8.9% |
| 2024 | 12.0% | 0.71× | 8.5% | 1.69× | 14.3% |
| 2025 | 8.0% | 0.66× | 5.2% | 1.68× | 8.8% |
| 2026 | 7.6% | 0.66× | 5.0% | 1.75× | 8.8% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 56,607 | 60,461 | 62,843 | 64,139 | 71,127 |
| Cost of revenue | 30,255 | 31,876 | 32,178 | 32,803 | 36,982 |
| Gross profit | 26,351 | 28,584 | 30,664 | 31,335 | 34,145 |
| SG&A | 21,556 | 23,476 | 24,164 | 26,003 | 28,311 |
| Operating income | 4,795 | 5,108 | 6,500 | 5,331 | 5,834 |
| Pretax income | 6,163 | 5,357 | 9,862 | 6,192 | 6,991 |
| Income tax | 1,873 | 1,118 | 2,316 | 1,091 | 1,366 |
| Net income attributable to owners | 4,290 | 4,238 | 7,545 | 5,101 | 5,424 |
| Operating margin | 8.5% | 8.4% | 10.3% | 8.3% | 8.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥17.1B | ¥17.5B | ¥16.7B | ¥10.6B | ¥10.1B |
| Total assets | ¥83.3B | ¥87.1B | ¥90.7B | ¥104.3B | ¥112.4B |
| Net assets | ¥48.9B | ¥54.5B | ¥61.9B | ¥71.8B | ¥76.8B |
| Share capital | ¥1.2B | ¥1.2B | ¥1.2B | ¥1.2B | ¥1.2B |
| Property, plant and equipment | ¥10.9B | ¥10.8B | ¥11.3B | ¥18.7B | ¥19.2B |
| Intangible assets excluding goodwill | ¥6.18B | ¥4.46B | ¥2.88B | ¥10.2B | ¥8.87B |
| Goodwill | — | — | — | ¥2.61B | ¥2.35B |
| Investment securities | ¥12.2B | ¥14.4B | ¥15.7B | ¥12.7B | ¥17.3B |
| Current assets | ¥49.6B | ¥53.8B | ¥56.1B | ¥58.3B | ¥61.4B |
| Current liabilities | ¥16B | ¥17.6B | ¥24B | ¥22.9B | ¥22.3B |
| Trade payables | ¥3.12B | — | — | — | — |
| Short-term borrowings | ¥300M | ¥300M | ¥300M | ¥2.52B | ¥1.71B |
| Long-term borrowings | ¥12.3B | ¥9.19B | ¥4.5B | ¥6.44B | ¥8.16B |
| Total liabilities | ¥34.4B | ¥32.6B | ¥28.8B | ¥32.5B | ¥35.6B |
| Non-controlling interests | — | — | — | ¥6.5B | ¥6.46B |
| Equity attributable to owners of parent | ¥45.4B | ¥49.3B | ¥56.1B | ¥60B | ¥63.9B |
| Retained earnings | ¥45.8B | ¥49.6B | ¥56.4B | ¥59.5B | ¥63.4B |
| Treasury stock | -¥3.48B | -¥3.35B | -¥3.29B | -¥704M | -¥658M |
EDINET (FSA Japan)
有価証券報告書－第5期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第4期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第3期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第2期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第1期(令和3年4月1日－令和4年3月31日)
Extracted from XBRL: 52 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.